Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.

Identifieur interne : 000138 ( Ncbi/Merge ); précédent : 000137; suivant : 000139

The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.

Auteurs : Xinqun Li [États-Unis] ; Zhen Fan

Source :

RBID : pubmed:20634405

Descripteurs français

English descriptors

Abstract

Autophagy is a regulated catabolic process triggered in cells deprived of nutrients or growth factors that govern nutrient uptake. Here, we report that autophagy is induced by cetuximab, a therapeutic antibody that blocks epidermal growth factor receptor function. Cancer cell treatment with cetuximab triggered autophagosome formation, conversion of microtubule-associated protein 1 light chain 3 from its cytoplasmic to membrane-associated form, and increased acidic vesicular organelle formation. Autophagy occurred when cetuximab inhibited the class I phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway, but not when it inhibited only the mitogen-activated protein/extracellular signal-regulated kinase kinase/Erk pathway, and it was accompanied by decreased levels of hypoxia inducible factor-1 alpha (HIF-1alpha) and Bcl-2. Stable overexpression of a HIF-1alpha mutant prevented cetuximab-induced autophagy and decrease in Bcl-2 levels. Knockdown of autophagy regulator beclin 1 or cell treatment with autophagy inhibitor 3-methyladenine, a class III PI3K (hVps34) inhibitor, also inhibited cetuximab-induced autophagy. Furthermore, knockdown of beclin 1 or Atg7 or treatment with the lysosome inhibitor chloroquine sensitized cancer cells to cetuximab-induced apoptosis. Mechanistic analysis argued that cetuximab acted by promoting an association between beclin 1 and hVps34, which was inhibited by overexpression of Bcl-2. Our findings suggest that the autophagy protects cancer cells from the proapoptotic effects of cetuximab.

DOI: 10.1158/0008-5472.CAN-10-0157
PubMed: 20634405

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:20634405

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.</title>
<author>
<name sortKey="Li, Xinqun" sort="Li, Xinqun" uniqKey="Li X" first="Xinqun" last="Li">Xinqun Li</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030</wicri:regionArea>
<wicri:noRegion>Texas 77030</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Fan, Zhen" sort="Fan, Zhen" uniqKey="Fan Z" first="Zhen" last="Fan">Zhen Fan</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20634405</idno>
<idno type="pmid">20634405</idno>
<idno type="doi">10.1158/0008-5472.CAN-10-0157</idno>
<idno type="wicri:Area/PubMed/Corpus">000395</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000395</idno>
<idno type="wicri:Area/PubMed/Curation">000395</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000395</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000381</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000381</idno>
<idno type="wicri:Area/Ncbi/Merge">000138</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.</title>
<author>
<name sortKey="Li, Xinqun" sort="Li, Xinqun" uniqKey="Li X" first="Xinqun" last="Li">Xinqun Li</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030</wicri:regionArea>
<wicri:noRegion>Texas 77030</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Fan, Zhen" sort="Fan, Zhen" uniqKey="Fan Z" first="Zhen" last="Fan">Zhen Fan</name>
</author>
</analytic>
<series>
<title level="j">Cancer research</title>
<idno type="eISSN">1538-7445</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (pathology)</term>
<term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Apoptosis Regulatory Proteins (metabolism)</term>
<term>Autophagy (drug effects)</term>
<term>Beclin-1</term>
<term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Carcinoma, Squamous Cell (drug therapy)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Cetuximab</term>
<term>Colorectal Neoplasms (drug therapy)</term>
<term>Colorectal Neoplasms (pathology)</term>
<term>Down-Regulation (drug effects)</term>
<term>ErbB Receptors (antagonists & inhibitors)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypoxia-Inducible Factor 1, alpha Subunit (biosynthesis)</term>
<term>Hypoxia-Inducible Factor 1, alpha Subunit (genetics)</term>
<term>Intracellular Signaling Peptides and Proteins (metabolism)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (pathology)</term>
<term>MAP Kinase Kinase Kinases (antagonists & inhibitors)</term>
<term>MAP Kinase Kinase Kinases (metabolism)</term>
<term>Membrane Proteins (metabolism)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (metabolism)</term>
<term>Neoplasms (pathology)</term>
<term>Phosphatidylinositol 3-Kinases (metabolism)</term>
<term>Phosphoinositide-3 Kinase Inhibitors</term>
<term>Protein-Serine-Threonine Kinases (metabolism)</term>
<term>Proto-Oncogene Proteins c-akt (antagonists & inhibitors)</term>
<term>Proto-Oncogene Proteins c-akt (metabolism)</term>
<term>Proto-Oncogene Proteins c-bcl-2 (biosynthesis)</term>
<term>Proto-Oncogene Proteins c-bcl-2 (genetics)</term>
<term>TOR Serine-Threonine Kinases</term>
<term>Vesicular Transport Proteins (metabolism)</term>
<term>Vulvar Neoplasms (drug therapy)</term>
<term>Vulvar Neoplasms (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adénocarcinome (anatomopathologie)</term>
<term>Adénocarcinome (traitement médicamenteux)</term>
<term>Anticorps monoclonaux (pharmacologie)</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Autophagie ()</term>
<term>Bécline-1</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Carcinome épidermoïde (traitement médicamenteux)</term>
<term>Cétuximab</term>
<term>Femelle</term>
<term>Humains</term>
<term>MAP Kinase Kinase Kinases (antagonistes et inhibiteurs)</term>
<term>MAP Kinase Kinase Kinases (métabolisme)</term>
<term>Phosphatidylinositol 3-kinases (métabolisme)</term>
<term>Protein-Serine-Threonine Kinases (métabolisme)</term>
<term>Protéines du transport vésiculaire (métabolisme)</term>
<term>Protéines et peptides de signalisation intracellulaire (métabolisme)</term>
<term>Protéines membranaires (métabolisme)</term>
<term>Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs)</term>
<term>Protéines proto-oncogènes c-akt (métabolisme)</term>
<term>Protéines proto-oncogènes c-bcl-2 (biosynthèse)</term>
<term>Protéines proto-oncogènes c-bcl-2 (génétique)</term>
<term>Protéines régulatrices de l'apoptose (métabolisme)</term>
<term>Récepteurs ErbB (antagonistes et inhibiteurs)</term>
<term>Régulation négative ()</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie (biosynthèse)</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie (génétique)</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (métabolisme)</term>
<term>Tumeurs (traitement médicamenteux)</term>
<term>Tumeurs colorectales (anatomopathologie)</term>
<term>Tumeurs colorectales (traitement médicamenteux)</term>
<term>Tumeurs de la vulve (anatomopathologie)</term>
<term>Tumeurs de la vulve (traitement médicamenteux)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>ErbB Receptors</term>
<term>MAP Kinase Kinase Kinases</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Hypoxia-Inducible Factor 1, alpha Subunit</term>
<term>Proto-Oncogene Proteins c-bcl-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Hypoxia-Inducible Factor 1, alpha Subunit</term>
<term>Proto-Oncogene Proteins c-bcl-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Apoptosis Regulatory Proteins</term>
<term>Intracellular Signaling Peptides and Proteins</term>
<term>MAP Kinase Kinase Kinases</term>
<term>Membrane Proteins</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Proto-Oncogene Proteins c-akt</term>
<term>Vesicular Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs</term>
<term>Tumeurs colorectales</term>
<term>Tumeurs de la vulve</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>MAP Kinase Kinase Kinases</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Récepteurs ErbB</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Protéines proto-oncogènes c-bcl-2</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Autophagy</term>
<term>Down-Regulation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Carcinoma, Squamous Cell</term>
<term>Colorectal Neoplasms</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
<term>Vulvar Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Protéines proto-oncogènes c-bcl-2</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Neoplasms</term>
<term>Phosphatidylinositol 3-Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>MAP Kinase Kinase Kinases</term>
<term>Phosphatidylinositol 3-kinases</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Protéines du transport vésiculaire</term>
<term>Protéines et peptides de signalisation intracellulaire</term>
<term>Protéines membranaires</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Protéines régulatrices de l'apoptose</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Carcinoma, Squamous Cell</term>
<term>Colorectal Neoplasms</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
<term>Vulvar Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Anticorps monoclonaux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs</term>
<term>Tumeurs colorectales</term>
<term>Tumeurs de la vulve</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Antibodies, Monoclonal, Humanized</term>
<term>Beclin-1</term>
<term>Cetuximab</term>
<term>Female</term>
<term>Humans</term>
<term>Phosphoinositide-3 Kinase Inhibitors</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Anticorps monoclonaux humanisés</term>
<term>Autophagie</term>
<term>Bécline-1</term>
<term>Cétuximab</term>
<term>Femelle</term>
<term>Humains</term>
<term>Régulation négative</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Autophagy is a regulated catabolic process triggered in cells deprived of nutrients or growth factors that govern nutrient uptake. Here, we report that autophagy is induced by cetuximab, a therapeutic antibody that blocks epidermal growth factor receptor function. Cancer cell treatment with cetuximab triggered autophagosome formation, conversion of microtubule-associated protein 1 light chain 3 from its cytoplasmic to membrane-associated form, and increased acidic vesicular organelle formation. Autophagy occurred when cetuximab inhibited the class I phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway, but not when it inhibited only the mitogen-activated protein/extracellular signal-regulated kinase kinase/Erk pathway, and it was accompanied by decreased levels of hypoxia inducible factor-1 alpha (HIF-1alpha) and Bcl-2. Stable overexpression of a HIF-1alpha mutant prevented cetuximab-induced autophagy and decrease in Bcl-2 levels. Knockdown of autophagy regulator beclin 1 or cell treatment with autophagy inhibitor 3-methyladenine, a class III PI3K (hVps34) inhibitor, also inhibited cetuximab-induced autophagy. Furthermore, knockdown of beclin 1 or Atg7 or treatment with the lysosome inhibitor chloroquine sensitized cancer cells to cetuximab-induced apoptosis. Mechanistic analysis argued that cetuximab acted by promoting an association between beclin 1 and hVps34, which was inhibited by overexpression of Bcl-2. Our findings suggest that the autophagy protects cancer cells from the proapoptotic effects of cetuximab.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20634405</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-7445</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>70</Volume>
<Issue>14</Issue>
<PubDate>
<Year>2010</Year>
<Month>Jul</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cancer research</Title>
<ISOAbbreviation>Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.</ArticleTitle>
<Pagination>
<MedlinePgn>5942-52</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-10-0157</ELocationID>
<Abstract>
<AbstractText>Autophagy is a regulated catabolic process triggered in cells deprived of nutrients or growth factors that govern nutrient uptake. Here, we report that autophagy is induced by cetuximab, a therapeutic antibody that blocks epidermal growth factor receptor function. Cancer cell treatment with cetuximab triggered autophagosome formation, conversion of microtubule-associated protein 1 light chain 3 from its cytoplasmic to membrane-associated form, and increased acidic vesicular organelle formation. Autophagy occurred when cetuximab inhibited the class I phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway, but not when it inhibited only the mitogen-activated protein/extracellular signal-regulated kinase kinase/Erk pathway, and it was accompanied by decreased levels of hypoxia inducible factor-1 alpha (HIF-1alpha) and Bcl-2. Stable overexpression of a HIF-1alpha mutant prevented cetuximab-induced autophagy and decrease in Bcl-2 levels. Knockdown of autophagy regulator beclin 1 or cell treatment with autophagy inhibitor 3-methyladenine, a class III PI3K (hVps34) inhibitor, also inhibited cetuximab-induced autophagy. Furthermore, knockdown of beclin 1 or Atg7 or treatment with the lysosome inhibitor chloroquine sensitized cancer cells to cetuximab-induced apoptosis. Mechanistic analysis argued that cetuximab acted by promoting an association between beclin 1 and hVps34, which was inhibited by overexpression of Bcl-2. Our findings suggest that the autophagy protects cancer cells from the proapoptotic effects of cetuximab.</AbstractText>
<CopyrightInformation>(c)2010 AACR.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xinqun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fan</LastName>
<ForeName>Zhen</ForeName>
<Initials>Z</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA129036-02</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>5R01CA129036</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA129036</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Res</MedlineTA>
<NlmUniqueID>2984705R</NlmUniqueID>
<ISSNLinking>0008-5472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491997">BECN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000071186">Beclin-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C419573">VPS35 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.25</RegistryNumber>
<NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>PQX0D8J21J</RegistryNumber>
<NameOfSubstance UI="D000068818">Cetuximab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000071186" MajorTopicYN="N">Beclin-1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000068818" MajorTopicYN="N">Cetuximab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020930" MajorTopicYN="N">MAP Kinase Kinase Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014846" MajorTopicYN="N">Vulvar Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">EGFR</Keyword>
<Keyword MajorTopicYN="N">autophagy</Keyword>
<Keyword MajorTopicYN="N">cetuximab</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20634405</ArticleId>
<ArticleId IdType="pii">70/14/5942</ArticleId>
<ArticleId IdType="doi">10.1158/0008-5472.CAN-10-0157</ArticleId>
<ArticleId IdType="pmc">PMC2933174</ArticleId>
<ArticleId IdType="mid">NIHMS210969</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Nature. 1999 Dec 9;402(6762):672-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10604474</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Apoptosis. 2009 Apr;14(4):376-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19172397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2000 Mar 15;60(6):1541-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10749120</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2000 Jun;82(12):1991-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10864208</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2000 Nov 1;19(21):5720-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11060023</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2000 Dec 1;290(5497):1717-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11099404</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2001 Apr 5;20(15):1913-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11313939</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biochem. 2002 May;131(5):647-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11983070</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2002 Aug 2;277(31):27975-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12032158</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2003 Jul 24;22(30):4734-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12879018</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12909240</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Dev Cell. 2003 Oct;5(4):539-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14536056</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Top Microbiol Immunol. 2004;279:73-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14560952</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14657337</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2003 Dec;112(12):1809-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14638851</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2004 Apr 12;23(16):2746-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15077138</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2004 Apr 12;23(16):2891-906</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15077152</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1992 Dec;12(12):5447-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1448077</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1993 Sep 15;53(18):4322-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8364927</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1993 Oct 1;53(19):4637-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8402640</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 1995 Apr;95(4):1897-905</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7706497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7539918</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1997 Dec 1;57(23):5328-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9393757</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1998 Jul 30;394(6692):485-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9697772</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 1998 Sep 1;17(17):5085-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9724644</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genomics. 1999 Jul 1;59(1):59-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10395800</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 Nov 5;306(5698):990-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15528435</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2005 Feb;25(3):1025-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15657430</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2005 Apr 15;65(8):3336-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15833867</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Mol Cell Biol. 2005 Jun;6(6):505-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15928714</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2005 Jun 23;24(27):4433-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15806152</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Sci. 2005 Jul 15;118(Pt 14):3091-102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15985464</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2005 Sep;5(9):726-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16148885</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2005 Sep 23;122(6):927-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16179260</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2006 Jan 26;25(4):525-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16170346</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4952-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16547133</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2006 May 12;281(19):13837-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16549426</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Cell Biol. 2006 Jul;8(7):688-99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16799551</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autophagy. 2006 Apr-Jun;2(2):85-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16874083</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autophagy. 2006 Apr-Jun;2(2):65-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16874090</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 2007 May 1;21(9):1037-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17437992</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pathobiology. 2007;74(3):169-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17643062</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2007 Sep 1;67(17):8240-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17804738</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer. 2007;6:63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17931419</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autophagy. 2008 Feb;4(2):195-204</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18059169</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2008 Apr 18;283(16):10892-903</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18281291</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2008 May;7(5):1207-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18483308</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autophagy. 2008 Jul;4(5):574-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18362515</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2008 Jun 20;30(6):678-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18570871</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FEBS Lett. 2000 Feb 18;468(1):53-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10683440</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Fan, Zhen" sort="Fan, Zhen" uniqKey="Fan Z" first="Zhen" last="Fan">Zhen Fan</name>
</noCountry>
<country name="États-Unis">
<noRegion>
<name sortKey="Li, Xinqun" sort="Li, Xinqun" uniqKey="Li X" first="Xinqun" last="Li">Xinqun Li</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000138 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000138 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:20634405
   |texte=   The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:20634405" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021